CD19

Chr 16AR

CD19 molecule

Also known as: B4, CVID3

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

GeneReviewsOMIMResearchGenerating clinical summary…
ARLOEUF 0.351 OMIM phenotype
Clinical SummaryCD19
🧬
Gene-Disease Validity (ClinGen)
immunodeficiency, common variable, 3 · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.90). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
17 unique Pathogenic / Likely Pathogenic· 182 VUS of 420 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — CD19
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.35LOEUF
pLI 0.905
Z-score 4.19
OE 0.17 (0.090.35)
Highly constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
1.03Z-score
OE missense 0.84 (0.760.93)
270 obs / 321.8 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.17 (0.090.35)
00.351.4
Missense OE?0.84 (0.760.93)
00.61.4
Synonymous OE?1.02
01.21.6
LoF obs/exp: 5 / 29.6Missense obs/exp: 270 / 321.8Syn Z: -0.22

ClinVar Variant Classifications

420 submitted variants in ClinVar

Classification Summary

Pathogenic10
Likely Pathogenic7
VUS182
Likely Benign189
Benign13
Conflicting17
10
Pathogenic
7
Likely Pathogenic
182
VUS
189
Likely Benign
13
Benign
17
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
7
1
2
0
10
Likely Pathogenic
6
1
0
0
7
VUS
2
160
17
3
182
Likely Benign
1
5
76
107
189
Benign
0
1
10
2
13
Conflicting
17
Total16168105112418

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

115 pathogenic / likely-pathogenic (of 156) ClinVar copy-number / structural variants overlap CD19 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

CD19 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

AIDS-Related Kaposi SarcomaSkin Kaposi Sarcoma

Nirogacestat in Patients With Kaposi Sarcoma

NOT YET RECRUITING
NCT07539454Phase PHASE2AIDS Malignancy ConsortiumStarted 2026-09-17
Biospecimen CollectionChest RadiographyComputed Tomography
SLE (Systemic Lupus)Lupus Erythematosus, SystemicLupus Nephritis

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

RECRUITING
NCT06925542Phase PHASE1CRISPR TherapeuticsStarted 2025-03-10
CTX112
B-cell Non Hodgkin Lymphoma (NHL)DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma (FL)

A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

RECRUITING
NCT07548697Phase EARLY_PHASE1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyStarted 2026-04-30
CT1182 injection
CD19 PositiveMixed Phenotype Acute Leukemia (MPAL)

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

RECRUITING
NCT07222579Phase PHASE2West Virginia UniversityStarted 2026-01-15
Subcutaneous Blinatumomab
Acute Lymphocytic Leukemia

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

RECRUITING
NCT06481735Phase PHASE1, PHASE2Chinese PLA General HospitalStarted 2025-02-15
TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cellFludarabineCyclophosphamide
Cutaneous Squamous Cell Carcinoma (CSCC)

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

RECRUITING
NCT07064330Instituto de Investigación Biomédica de SalamancaStarted 2025-07-17
Cemiplimab
Acute Lymphocytic Leukemia

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL

RECRUITING
NCT07008885Phase PHASE1, PHASE2Chinese PLA General HospitalStarted 2025-06-20
CAR19TIF cellsFludarabineCyclophosphamide
Advanced Solid Tumors

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

ACTIVE NOT RECRUITING
NCT05914376Phase PHASE1Hangzhou Converd Co., Ltd.Started 2023-07-05
Recombinant human IL-21-expressing oncolytic vaccinia virus injection
B Cell LymphomaChronic Lymphocytic LeukemiaAcute Lymphocytic Leukemia

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

ACTIVE NOT RECRUITING
NCT00586391Phase PHASE1Baylor College of MedicineStarted 2009-02
CD19CAR-28-zeta T cellsIpilimumab
Acute Lymphoblastic Leukemia

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

RECRUITING
NCT06735690Phase EARLY_PHASE1City of Hope Medical CenterStarted 2025-12-30
Allogeneic Hematopoietic Stem Cell TransplantationAnti-CD19-CAR CMV-specific T-lymphocytesBiospecimen Collection
Primary Immune Thrombocytopenia (ITP)

A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

NOT YET RECRUITING
NCT07660172Phase PHASE2Novartis PharmaceuticalsStarted 2027-02-08
IanalumabEltrombopag
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

RECRUITING
NCT05418088Phase PHASE1Sumithira VasuStarted 2022-06-30
Anti-CD19/CD20/CD22 CAR T-CellsCyclophosphamideFludarabine Phosphate